Creatine

Creatine

SCHEMBL623785

CN(CC(=O)O)C(=N)N.O=C(O)CC(O)C(=O)O

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

CACNA1CCACNA1DCACNA1FCACNA1SDRD2HTR1BHTR1DHTR1F

The experimentally established mechanism targets of Creatine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.52
NOS3 P29474 1/20 0.42
NOS1 P29475 1/20 0.42
NOS2 P35228 1/20 0.42
TET2 Q6N021 6/20 0.33
TET3 O43151 2/20 0.33
TET1 Q8NFU7 1/20 0.33
CA1 P00915 5/20 0.33
CA2 P00918 5/20 0.33
GABRR1 P24046 2/20 0.31
KDM4A O75164 2/20 0.31
KDM4C Q9H3R0 2/20 0.31
KDM2A Q9Y2K7 2/20 0.31
LMNA P02545 1/20 0.31
SLC22A6 Q4U2R8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Creatine SCHEMBL29400407 1.00 SMN1; SMN2 (0.52) SMN1; SMN2NOS3NOS1NOS2TET2
Creatine SCHEMBL29404550 1.00 SMN1; SMN2 (0.52) SMN1; SMN2NOS3NOS1NOS2TET2
Cadaverine Tartrate SCHEMBL1286961 0.85 NOS3 (0.47) NOS3NOS1NOS2CA1CA2
Creatine SCHEMBL4281967 0.84 NOS3 (0.40) NOS3NOS1NOS2CA1CA2
Creatine SCHEMBL1883324 0.84 NOS3 (0.46) NOS3NOS1NOS2CA1CA2
Malic Acid SCHEMBL31238937 0.84 CA12 (0.43) SMN1; SMN2NOS3NOS1NOS2CA1
Creatine SCHEMBL31156412 0.83 NOS3 (0.44) NOS3NOS1NOS2CA1CA2
Creatine SCHEMBL30063981 0.83
Creatine SCHEMBL21567 0.83
Creatine SCHEMBL27979093 0.83 NOS3 (0.46) NOS3NOS1NOS2CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 290 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240138438-A1 CREATINE NUTRITIONAL SUPPLEMENT MENTER DYLAN (US) 2024-05-02 US claimed
US-11865097-B2 Creatine nutritional supplement MENTER DYLAN (US) 2024-01-09 US claimed
US-20230233499-A1 CREATINE NUTRITIONAL SUPPLEMENT MENTER DYLAN (US) 2023-07-27 US claimed
US-11690858-B1 Neuroprotective mixture for mitigating the harmful effects of ischemic stroke TRICERAPRO HOLDING, LLC (US) 2023-07-04 US claimed
US-11642327-B2 Creatine nutritional supplement MENTER DYLAN ROBERT (US) 2023-05-09 US claimed
US-20230108723-A1 Multi-Nutrient Composition EXERKINE CORPORATION (CA) 2023-04-06 US claimed
US-11504413-B2 Multi-nutrient composition EXERKINE CORPORATION (CA) 2022-11-22 US claimed
US-20220287346-A1 STABLE CREATINE BEVERAGES THE COCA-COLA COMPANY 2022-09-15 US claimed
EP-4017282-A1 STABLE CREATINE BEVERAGES The Coca-Cola Company (US) 2022-06-29 EP claimed
US-20220054442-A1 Creatine Nutritional Supplement MENTER DYLAN (US) 2022-02-24 US claimed
EP-1744732-A2 NUTRITIONAL COMPOSITION FOR INCREASING CREATINE UPTAKE IN SKELETAL MUSCLE Thermo Formulations Ltd. (CA) 2007-01-24 EP claimed
US-20060280814-A1 Nutritional composition for increasing creatine uptake in skeletal muscle GARDINER PAUL T 2006-12-14 US claimed
WO-2005110448-A2 NUTRITIONAL COMPOSITION FOR INCREASING CREATINE UPTAKE IN SKELETAL MUSCLE THERMO FORMULATIONS LTD. (CA) 2005-11-24 WO claimed
WO-2005107735-A2 NUTRITIONAL COMPOSITION FOR ENHANCING LEAN MUSCLE STIMULUS, GROWTH, STRENGTH AND RECOVERY, CREATING AND PROLONGING INTENSE MUSCLE PUMPS, SUPPORTING ENDURANCE, STRENGTH, PERFORMANCE, SIZE AND STAMINA, PROVIDING A TRANSDUCER EFFECT FOR NITRIC OXIDE, INCRESING NUTRIENT DELIVERY AND/OR PROMOTING INCREASED VASCULAR RESPONSE IN A PUMP FORMULATIONS, LTD. (CA) 2005-11-17 WO claimed
CN-1224328-C Use of creatine as fodder additive DSM FINE CHEM AUSTRIA GMBH (AT) 2005-10-26 CN claimed
EP-1176875-B1 USE OF CREATINE AS A FEED SUBSTITUTE DSM FINE CHEM AUSTRIA GMBH (AT) 2005-01-19 EP claimed
US-20040228884-A1 Ion-pair delivery system for cosmetic and pharmaceutical compositions GUPTA SHYAM K (US) 2004-11-18 US claimed
US-20040156873-A1 Topically Bioavailable Acne and Rosacea Treatment Compositions GUPTA SHYAM K (US) 2004-08-12 US claimed
US-20040092482-A1 Hydroxy acids based delivery systems for skin resurfacing and anti-aging compositions GUPTA SHYAM K (US) 2004-05-13 US claimed
CN-1350434-A Use of creatine as fodder additive DSM FINE CHEMICALS AUSTRIA (AT) 2002-05-22 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092482-A1 Hydroxy acids based delivery systems for skin resurfacing and anti-aging compositions CUTA, HIRA, HARS1 SMN1; SMN2 4162/4885NOS3 2825/4885NOS1 2319/4885
US-20060280814-A1 Nutritional composition for increasing creatine uptake in skeletal muscle CPT1B, CKMT1A; CKMT1B, MTPN SMN1; SMN2 354/4885NOS3 922/4885NOS1 352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.